Integrating systemic therapy into larynx preservation: Lessons from 3 decades of progress
This invited editorial provides an overview of the efficacy of systemic therapy in larynx preservation within the context of the 20‐year outcomes reported by Cunha et al. in this issue of Cancer . Putting these results within the context of cumulative practice‐changing studies reinforces the central role systemic therapy stands to play in the prospects of organ preservation.
Authors
- N. Schmitt
- Nabil Saba
- Yong Teng
- Jose A. Monteiro
Institutions
- Emory University (US)
- Piedmont Cancer Institute (US)
Publication Details
- Journal
- Cancer
- Published
- 2026-01-21
- DOI
- https://doi.org/10.1002/cncr.70258
- Primary Topic
- Voice and Speech Disorders
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Bristol-Myers Squibb
- Pfizer
- AstraZeneca
- GlaxoSmithKline
- Regeneron Pharmaceuticals
- Exelixis
- Celldex Therapeutics
- Astex Pharmaceuticals
- UroGen Pharma
- Seagen
- Coherus Biosciences
- Eisai
- National Institutes of Health
- EMD Serono